What Can G1 Therapeutics Inc. (NASDAQ: GTHX) Expect In 2021? – Stocks Register
Home  »  Finance   »  What Can G1 Therapeutics Inc. (NASDAQ: GTHX) Expec...

What Can G1 Therapeutics Inc. (NASDAQ: GTHX) Expect In 2021?

G1 Therapeutics Inc. (NASDAQ:GTHX) price on Friday, October 08, fall -2.25% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $12.14.

A look at the stock’s price movement, the close in the last trading session was $12.42, moving within a range at $12.10 and $12.55. The beta value (5-Year monthly) was 2.17. Turning to its 52-week performance, $37.07 and $10.81 were the 52-week high and 52-week low respectively. Overall, GTHX moved -18.74% over the past month.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


G1 Therapeutics Inc.’s market cap currently stands at around $508.42 million, with investors looking forward to this quarter’s earnings report slated for May 05, 2021. Analysts project the company’s earnings per share (EPS) to be -$0.99, which has seen fiscal year 2021 EPS growth forecast to increase to -$3.6 and about -$3.59 for fiscal year 2022. Per the data, EPS growth is expected to be -37.40% for 2021 and 0.30% for the next financial year.

Analysts have a consensus estimate of $5.79 million for the company’s revenue for the quarter, with a low and high estimate of $4 million and $8 million respectively. The average forecast suggests down to a -78.20% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $32.3 million, representing a -28.70% decline on that reported in the last financial year.

Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that GTHX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.

GTHX’s current price about -15.24% and -18.07% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 31.50, while 7-day volatility ratio is 4.99% and 4.96% in the 30-day chart. Further, G1 Therapeutics Inc. (GTHX) has a beta value of 2.18, and an average true range (ATR) of 0.69.

In the market, a comparison of G1 Therapeutics Inc. (GTHX) and its peers suggest the former has performed considerably weaker. Data shows GTHX’s intraday price has changed -2.25% in last session and -6.90% over the past year. Looking at another peer, we see that Omeros Corporation (OMER) price has dipped -9.83% on the day. However, the stock is -40.55% off its price a year ago. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.19% and -0.03% respectively in the last trading.

If we refocus on G1 Therapeutics Inc. (NASDAQ:GTHX), historical trading data shows that trading volumes averaged 1.16 million over the past 10 days and 1.02 million over the past 3 months. The company’s latest data on shares outstanding shows there are 42.12 million shares.

>> 7 Top Picks for the Post-Pandemic Economy <<

The 0.70% of G1 Therapeutics Inc.’s shares are in the hands of company insiders while institutional holders own 70.60% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 7.35 million on Sep 14, 2021, giving us a short ratio of 9.29. The data shows that as of Sep 14, 2021 short interest in G1 Therapeutics Inc. (GTHX) stood at 17.36% of shares outstanding, with shares short falling to 7.54 million registered in Aug 12, 2021. Current price change has pushed the stock -32.52% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the GTHX stock continues to rise going into the next quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam